Radiopharm Theranostics Limited American Depositary SharesRADX
Mentioned
Impact on stocks 1
Health Care
Radiopharm Theranostics Limited American Depositary SharesRadiopharm Theranostics Limited American Depositary SharesRadiopharm Theranostics announced positive results from the Phase 2b clinical trial of its imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint. The company plans to initiate a Phase 3 registrational trial for RAD 101 in the fourth quarter of 2026. Following the close of the quarter, Radiopharm raised approximately 12.5 million dollars through an institutional offer and launched a 6 million dollar Share Purchase Plan. The company also provided updates across its pipeline, including early clinical signs of a partial response in the third cohort of its RAD 204 Phase 1 trial. Closing cash at the end of the quarter was 4.1 million dollars, down from 19.2 million dollars in the prior quarter.